QC
SUPN icon

Quent Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Quent Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,000
Closed -$116K – 1276
2022
Q2 		$116K Buy
+4,000
New +$115K 0.02% 322

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quent Capital's SUPN Position: Q3 2022 in Review

Quent Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2022, closing a stake of 4,000 shares — an estimated $116K sold.

Quent Capital first reported a position in SUPN in Q2 2022 and held it in 1 quarter. The position peaked at $116K in Q2 2022. 244 funds tracked by Wall St. Rank hold SUPN as of Q3 2022.

  • Quent Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Quent Capital sold 4,000 Supernus Pharmaceuticals shares in Q3 2022, an estimated $116K.
  • Quent Capital first reported a position in Supernus Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Quent Capital's Supernus Pharmaceuticals position peaked at $116K in Q2 2022.
  • 244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2022.

Based on Quent Capital's 13F filing for Q3 2022, filed 10 Nov 2022.